Based Research Foundation focuses on the translation layer between AI-generated therapeutic candidates and clinical trials. The work sits in the space now described by regulators and translational researchers as new approach methodologies: human-relevant in-vitro systems, computational models, and related tools that can improve the predictive relevance of nonclinical evidence.
This benchmark image summarizes how assay outputs are linked to decision outcomes before candidate promotion.
Clinical trials in a dish
“Clinical trials in a dish” is a practical shorthand for testing candidate therapies in human-relevant biological systems before a program moves toward patients. It does not mean replacing clinical trials. It means bringing more clinical discipline into preclinical evidence: context of use, reproducible endpoints, and a clear link between assay behavior and the next decision.
FDA materials on new approach methodologies describe in-vitro human-based systems and in-silico models as tools that may improve the human relevance of nonclinical testing. The foundation focuses on the evidence chain around those tools.
Organoid and tissue models
Organoids and patient-derived cultures can preserve aspects of tissue organization, disease biology, and treatment response that flat cell systems may miss. Recent review literature frames organoids as useful platforms for disease modeling, drug screening, and safety evaluation while emphasizing standardization, scalability, and regulatory adoption as continuing challenges.
The foundation’s interest is the benchmark question: when does an organoid result become strong enough to change what a sponsor, funder, or translational team does next?
Microphysiological systems
Tissue chips and organ-on-chip systems add engineered microenvironments, flow, and mechanical or biochemical cues to model specific tissue functions. NCATS describes its Tissue Chip program as an effort to improve prediction of whether drugs will be safe or toxic in humans.
For AI-generated candidate pipelines, these systems matter because they can make candidate triage less dependent on a single static screen and more dependent on measured biological behavior.
Useful references
The program follows public field context around new approach methodologies, tissue chips, and organoid models for drug discovery.
